Peel Hunt Reiterates Buy Rating for Silence Therapeutics (SLN)

Silence Therapeutics (LON:SLN)‘s stock had its “buy” rating reiterated by analysts at Peel Hunt in a research note issued on Thursday. They presently have a GBX 275 ($3.68) price objective on the stock. Peel Hunt’s price objective would indicate a potential upside of 41.39% from the company’s previous close.

Shares of Silence Therapeutics (LON SLN) opened at GBX 194.50 ($2.60) on Thursday. Silence Therapeutics has a 12 month low of GBX 71.88 ($0.96) and a 12 month high of GBX 254.75 ($3.41). The company has a market cap of $138.32 and a P/E ratio of -1,496.15.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at

About Silence Therapeutics

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply